title: Effects of Mycobacterium avium complex-infection treatment on cytokine expression in human immunodeficiency virus-infected persons: results of AIDS clinical trials group protocol 853.
abstract: Human immunodeficiency virus (HIV) type 1-infected persons with newly diagnosed Mycobacterium avium complex (MAC) bacteremia were enrolled in an 8-week study to determine whether treatment of MAC infection is associated with decreases in plasma tumor necrosis factor (TNF)-alpha levels. Blood specimens were obtained for quantitative MAC cultures and to determine plasma levels of HIV RNA, TNF-alpha, and other proinflammatory cytokines. MAC levels decreased by 1.75 log at week 4 (P=.008) and by 2.48 log at week 8 (P=.001). Plasma TNF-alpha decreased by 0.15 log at week 4 (P=.042) and by 0. 40 log at week 8 (P=.027). Plasma interleukin (IL)-6 decreased by 0. 56 log at week 8 (P=.039). There were nonsignificant trends (P<.10) for plasma levels of IL-1beta and HIV RNA to decrease at week 8. Nonsignificant decreases in plasma levels of TNF-alpha, IL-1beta, IL-6, and HIV RNA were also seen in those individuals who remained on stable antiretroviral therapy throughout the 8 weeks of the study.
authors.affiliation: Wayne State University, Department of Medicine, Division of Infectious Diseases, Detroit, MI 48201, USA. macarthur@intmed.wayne.edu
authors.forename: R D
authors.initials: RD
authors.lastname: MacArthur
authors.forename: M M
authors.initials: MM
authors.lastname: Lederman
authors.forename: C A
authors.initials: CA
authors.lastname: Benson
authors.forename: M C
authors.initials: MC
authors.lastname: Chernoff
authors.forename: R R
authors.initials: RR
authors.lastname: MacGregor
authors.forename: J
authors.initials: J
authors.lastname: Spritzler
authors.forename: L F
authors.initials: LF
authors.lastname: Mahon
authors.forename: B
authors.initials: B
authors.lastname: Yen-Lieberman
authors.forename: S
authors.initials: S
authors.lastname: Purvis
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000097:blood* / Q000188:drug therapy*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D016207:Cytokines / Q000097:blood*; D004977:Ethambutol / Q000627:therapeutic use; D006801:Humans; D007375:Interleukin-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D015270:Mycobacterium avium-intracellulare Infection / Q000097:blood* / Q000188:drug therapy*; D010865:Pilot Projects; D012367:RNA, Viral / Q000032:analysis; D017828:Rifabutin / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D019562:Viral Load
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D016207:Cytokines; D007375:Interleukin-1; D015850:Interleukin-6; D012367:RNA, Viral; D014409:Tumor Necrosis Factor-alpha; D017828:Rifabutin; D004977:Ethambutol; D017291:Clarithromycin